Online citations, reference lists, and bibliographies.
← Back to Search

Differential Expression Of Ki-67 And Sex Steroid Hormone Receptors Between Genders In Peritoneal Mesothelioma

Terence C. Chua, Peng Yao, Javed Akther, L. Young, S. Bao, U. Samaraweera, T. Yan, D. Morris
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Gender influence on survival in mesothelioma has been observed in several large clinical series. However, this gender effect has not been investigated. Female patients often have less aggressive tumors and survive longer. However, few studies in the literature have explained the molecular basis of this finding. Understanding this difference at a molecular level may offer the hope of improving survival via hormonal manipulation.We investigate the expression of Ki-67 and sex steroid receptors; estrogen receptors (ER), progesterone receptors (PR) and androgen receptors (AR) to elucidate any pathognomonic difference that characterize this gender difference. Positive expression of markers was observed in 95% (Ki-67), 80% (ER), 100% (PR) and 65% (AR) of patients. Expression of markers between gender showed a higher Ki-67 in males (M = 1.3%, F = 0.6%), higher estrogen receptor in females (M = 0.6%, F = 1.7%) and higher progesterone receptor in females (M = 1.0%, F = 1.4%). Twenty patients were treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in our peritonectomy unit. Paraffin sections of the tumor specimens were retrieved for immunohistochemical analysis. The immunostaining was performed using monoclonal mouse anti-human antibodies on an autostainer (Autostainer Plus; Dako, Inc.). The intensity of the stains were quantified using the Image-Pro Plus (IPP) 4.5 (Media Cybernetics, Silver Spring, MD). For the first time, we demonstrate the presence of sex steroid receptors in peritoneal mesothelioma. Once the exact functional effects of these receptors are understood, the use of established therapeutic options that are clinically available to target the sex steroid pathway may become a reality.
This paper references
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma
B Castagneto (2008)
10.1309/8FCHQ3VPBWM7B5X9
Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful.
R. Barnetson (2006)
10.1016/0002-9378(57)90180-1
Diseases of the Breast
C. Haagensen (1971)
Progesterone induces apoptosis in malignant mesothelioma cells.
K. Horita (2001)
10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO;2-5
Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases
V. Adams (1986)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.1016/j.athoracsur.2008.01.088
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
T. Mineo (2008)
10.1210/ER.2007-0019
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex.
H. Heemers (2007)
10.1053/RMED.2001.1178
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
M. Metintas (2001)
10.1111/1523-1747.EP12277396
Nuclear size and shape parameters correlate with proliferative activity in cutaneous melanocytic tumors.
J. Smolle (1989)
10.3816/CLC.2005.N.020
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
P. Jänne (2005)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1378/CHEST.109.1.109
Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
L. Johansson (1996)
10.1016/S0039-128X(00)00112-4
Progesterone receptor coactivators
B. Rowan (2000)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
Progesterone receptor coactivators. Steroids
BG Rowan (2000)
10.1016/0002-9343(80)90103-5
Multimodality therapy for malignant mesothelioma based on a study of natural history.
K. H. Antman (1980)
10.1210/EDRV.20.3.0366
Nuclear receptor coregulators: cellular and molecular biology.
N. McKenna (1999)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1002/bjs.5377
Sex difference in diffuse malignant peritoneal mesothelioma
T. Yan (2006)
10.1200/JCO.2005.09.004
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
X. Cui (2005)
10.1186/1476-4598-1-7
The roles of sex steroid receptor coregulators in cancer
Xiuhua Gao (2002)
10.1016/S1055-3207(03)00045-0
A review of peritoneal mesothelioma at the Washington Cancer Institute.
P. Sugarbaker (2003)
10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
The Ki‐67 protein: From the known and the unknown
T. Scholzen (2000)
Factors influencing long-term survival in mesothelioma patients–results of the German mesothelioma
V Neumann (2004)
10.1056/NEJM198902233200802
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
B. Fisher (1989)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1634/theoncologist.2007-0199
The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.
P. Ryan (2008)
Endocrine Approaches in the Therapy of Prostate Carcinoma
Chen Lam Hiew (2011)
10.1093/ANNONC/MDL428
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
T. Yan (2007)
10.1007/S00420-003-0498-6
Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register
V. Neumann (2004)
10.1093/ANNONC/MDL345
Epidemiology of peritoneal mesothelioma: a review.
P. Boffetta (2007)
10.1177/030089160308900307
Clinical Presentation of Peritoneal Mesothelioma
Y. Acherman (2003)
10.1210/ER.2003-0023
Coregulator function: a key to understanding tissue specificity of selective receptor modulators.
C. L. Smith (2004)
10.1210/EDRV-11-2-201
Steroid receptor family: structure and functions.
M. A. Carson-Jurica (1990)
10.3109/9780203909249-9
The Importance of the Estrogen Receptor in Breast Cancer
R. Schiff (2002)
10.1097/00000658-199501000-00004
Peritonectomy Procedures
P. Sugarbaker (2003)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
Advances inmalignant mesothelioma
RobinsonBW (2005)
10.1201/b14039-7
The Importance of the Estrogen Receptor in Breast Cancer
R. Schiff (2002)
10.1016/J.EJSO.2006.03.009
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
R. García-Carbonero (2006)
10.1053/HUPA.2003.31
Benign cystic mesothelioma of the peritoneum: a clinicopathologic study of 17 cases and immunohistochemical analysis of estrogen and progesterone receptor status.
R. Sawh (2003)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.EJSO.2006.05.009
Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma.
T. Yan (2006)



This paper is referenced by
10.1016/j.ejso.2015.07.004
Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Y. Huang (2015)
10.4081/JOPER.2017.52
Multicystic mesothelioma has malignant potential: its grounds and mechanisms of peritoneal metastasis
Y. Yonemura (2017)
10.1186/s12957-015-0624-4
Effects of sex hormones on survival of peritoneal mesothelioma
Y. Huang (2015)
10.7189/jogh.10.010701
Gender equality and global health: intersecting political challenges
B. Cislaghi (2020)
10.1002/jcp.22724
Malignant mesothelioma: Facts, Myths, and Hypotheses
M. Carbone (2012)
10.1074/jbc.M111.337378
Phosphodiesterase 4B Mediates Extracellular Signal-regulated Kinase-dependent Up-regulation of Mucin MUC5AC Protein by Streptococcus pneumoniae by Inhibiting cAMP-protein Kinase A-dependent MKP-1 Phosphatase Pathway*
Ji-Yun Lee (2012)
10.1016/j.canlet.2018.09.001
Regulation of sex hormone receptors in sexual dimorphism of human cancers.
Daoshan Zheng (2018)
10.1097/COC.0b013e3182a0e867
Prognostic Significance of Ki67 Expression in Malignant Peritoneal Mesothelioma
K. Pillai (2015)
10.1002/ijc.32931
Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population‐based study
E. Sirri (2020)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal sarcomatosis: long-term outcome from a single institution experience.
A. Sommariva (2013)
10.1016/j.ctrv.2011.10.006
Diffuse malignant peritoneal mesothelioma--an update on treatment.
Peyman Mirarabshahii (2012)
10.5539/JMBR.V3N1P1
Osteonectin (SPARC) Is a Key Regulator of Malignant Pleural Mesothelioma
Fauzia Siddiq (2013)
10.1016/j.humpath.2018.07.003
IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
S. Hui (2018)
10.1007/s10555-014-9543-z
Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities
J. Muñoz (2014)
10.1158/1535-7163.MCT-12-1103
Cyclooxygenase-2, Epidermal Growth Factor Receptor, and Aromatase Signaling in Inflammation and Mesothelioma
B. Nuvoli (2013)
10.1007/s00432-013-1517-y
Peritoneal metastases of lower gastrointestinal tract origin: a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy
L. Ung (2013)
10.1016/j.ejca.2013.05.027
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
D. Baratti (2013)
10.1016/j.ejso.2010.08.130
Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
D. Baratti (2010)
10.1016/j.etap.2013.12.001
Effects of Th1 and Th2 cells balance in pulmonary injury induced by nano titanium dioxide.
Xuhong Chang (2014)
10.1093/annonc/mdr477
Importance of gender in diffuse malignant peritoneal mesothelioma.
C. Cao (2012)
Semantic Scholar Logo Some data provided by SemanticScholar